MLYS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update on Lorundrostat

Nov 4, 2026

8-K

Mineralys Therapeutics Terminates License Agreement with Tanabe and Secures Full Assignment of Lorundrostat Patents

Oct 29, 2026

8-K

Mineralys Therapeutics Appoints Kristine Peterson and Lonnel Coats to Board of Directors

Oct 19, 2026

8-K

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 11, 2026

8-K

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Jun 3, 2026

8-K

Mineralys Therapeutics Amends Tanabe License Agreement and Secures $500 Million Senior Secured Term Loan

Jun 3, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jun 3, 2026

424B5

REGISTERED OFFERING

Sep 3, 2025

424B5

PENDING FIXED PRICE OFFERING

Sep 2, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 12, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 10, 2025

424B5

ATM | Offering amount: $100,000,000

Apr 11, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 13, 2026

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Nov 10, 2025

S-3MEF

Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]

Sep 2, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 14, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 12, 2024

S-3/A

SHELF EFFECTIVE

Mar 29, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 8, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 8, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Peterson Kristine (Reporting)

Oct 20, 2026

Peterson Kristine (Reporting)

Oct 20, 2026

COATS LONNEL (Reporting)

Oct 20, 2026

COATS LONNEL (Reporting)

Oct 20, 2026

144

Form 144 - Report of proposed sale of securities

Oct 13, 2026

Congleton Jon (Reporting)

Oct 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 12, 2024

CORRESP

Form CORRESP - Correspondence

Apr 9, 2024

LETTER

Form UPLOAD - SEC-generated letter

Mar 26, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 10, 2023

CORRESP

Form CORRESP - Correspondence

Feb 7, 2023

CORRESP

Form CORRESP - Correspondence

Feb 7, 2023

Mineralys Therapeutics, Inc. MLYS · SEC Filings